Paul Tudor Jones's BIO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 5,161 shares of Bio-Rad Laboratories, Inc. (BIO) worth $1.44 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2016, adding 54,616 shares. Largest reduction occurred in Q1 2015, reducing 50,917 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +5,161 | New Buy | 5,161 | $278.75 |
| Q1 2025 | -7,433 | Sold Out | 0 | $0.00 |
| Q4 2024 | +7,433 | New Buy | 7,433 | $328.51 |
| Q1 2024 | -16,070 | Sold Out | 0 | $0.00 |
| Q4 2023 | +9,015 | Add 127.78% | 16,070 | $322.89 |
| Q3 2023 | +7,055 | New Buy | 7,055 | $358.45 |
| Q2 2023 | -13,759 | Sold Out | 0 | $0.00 |
| Q1 2023 | -1,554 | Reduce 10.15% | 13,759 | $0.48 |
| Q4 2022 | +2,730 | Add 21.70% | 15,313 | $0.42 |
| Q3 2022 | +11,645 | Add 1241.47% | 12,583 | $417.15 |
| Q2 2022 | -5,298 | Reduce 84.96% | 938 | $494.67 |
| Q1 2022 | -113 | Reduce 1.78% | 6,236 | $563.18 |
| Q4 2021 | +5,812 | Add 1082.31% | 6,349 | $755.55 |
| Q3 2021 | -6,291 | Reduce 92.14% | 537 | $746.74 |
| Q2 2021 | +351 | Add 5.42% | 6,828 | $644.26 |
| Q1 2021 | +6,071 | Add 1495.32% | 6,477 | $571.10 |
| Q4 2020 | -5,033 | Reduce 92.54% | 406 | $583.74 |
| Q3 2020 | +2,586 | Add 90.64% | 5,439 | $515.54 |
| Q2 2020 | +2,853 | New Buy | 2,853 | $451.45 |
| Q4 2018 | -1,917 | Sold Out | 0 | $0.00 |
| Q3 2018 | +1,917 | New Buy | 1,917 | $312.99 |
| Q1 2018 | -2,580 | Sold Out | 0 | $0.00 |
| Q4 2017 | +2,580 | New Buy | 2,580 | $238.76 |
| Q3 2017 | -9,000 | Sold Out | 0 | $0.00 |
| Q2 2017 | -1,722 | Reduce 16.06% | 9,000 | $226.33 |
| Q1 2017 | -48,378 | Reduce 81.86% | 10,722 | $199.31 |
| Q4 2016 | +54,616 | Add 1218.02% | 59,100 | $182.28 |
| Q3 2016 | +4,484 | New Buy | 4,484 | $163.92 |
| Q2 2016 | -3,335 | Sold Out | 0 | $0.00 |
| Q1 2016 | -265 | Reduce 7.36% | 3,335 | $136.73 |
| Q4 2015 | +156 | Add 4.53% | 3,600 | $138.61 |
| Q3 2015 | -2,487 | Reduce 41.93% | 3,444 | $134.44 |
| Q2 2015 | -1,712 | Reduce 22.40% | 5,931 | $150.56 |
| Q1 2015 | -50,917 | Reduce 86.95% | 7,643 | $135.16 |
| Q4 2014 | +50,546 | Add 630.72% | 58,560 | $120.56 |
| Q3 2014 | +2,064 | Add 34.69% | 8,014 | $113.43 |
| Q2 2014 | +300 | Add 5.31% | 5,950 | $119.66 |
| Q1 2014 | -1,795 | Reduce 24.11% | 5,650 | $128.14 |
| Q4 2013 | +2,845 | Add 61.85% | 7,445 | $123.57 |
| Q3 2013 | +100 | Add 2.22% | 4,600 | $117.61 |
| Q2 2013 | +4,500 | Add 0.00% | 4,500 | $112.22 |
Paul Tudor Jones's Bio-Rad Laboratories Investment FAQs
Paul Tudor Jones first purchased Bio-Rad Laboratories, Inc. (BIO) in Q2 2013, acquiring 4,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Bio-Rad Laboratories, Inc. (BIO) for 41 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q4 2016, adding 59,100 shares worth $10.77 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 5,161 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $1.44 M.
As of the Q1 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 59,100 shares, as reported at the end of Q4 2016.